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Abstract
Single genetic variants discovered so far have been only weakly associated with melanoma. This study aims to use
multiple single nucleotide polymorphisms (SNPs) jointly to obtain a larger genetic effect and to improve the predictive
value of a conventional phenotypic model. We analyzed 11 SNPs that were associated with melanoma risk in
previous studies and were genotyped in MD Anderson Cancer Center (MDACC) and Harvard Medical School
investigations. Participants with ≥15 risk alleles were 5-fold more likely to have melanoma compared to those
carrying ≤6. Compared to a model using the most significant single variant rs12913832, the increase in predictive
value for the model using a polygenic risk score (PRS) comprised of 11 SNPs was 0.07(95% CI, 0.05-0.07). The
overall predictive value of the PRS together with conventional phenotypic factors in the MDACC population was 0.69
(95% CI, 0.64-0.69). PRS significantly improved the risk prediction and reclassification in melanoma as compared
with the conventional model. Our study suggests that a polygenic profile can improve the predictive value of an
individual gene polymorphism and may be able to significantly improve the predictive value beyond conventional
phenotypic melanoma risk factors.
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Introduction
The incidence rate of melanoma has substantially increased
among all white populations during the past several
decades[1]. In 2013 in the United States, about 76,690 new
cases of melanoma are expected to be diagnosed, and 9,480
patients will die of this disease[2]. Melanoma is highly curable if
discovered and treated early. Melanoma patient outcome
varies significantly by stage; the overall 5-year survival rates for
patients with localized melanoma or regional spread are
approximately 98% and 62%, respectively, while for patients
with distant metastatic disease, the 5-year survival rate is only
about 15%[3,4]. Recent data suggests that systematic skin
cancer screening can potentially reduce melanoma-associated
mortality; broad population-based screening programs based
on clinical evaluations of largely low risk individuals, however,
are likely to be prohibitively expensive [5]. Therefore, an
effective risk assessment tool is needed to help primary care
providers identify individuals at high risk for melanoma. Risk
factors for melanoma include a family history of the disease,
fair pigmentation, multiple nevi, immunosuppression,
intermittent exposure to ultraviolet radiation, and genetic
determinants [6]. Familial aggregation of melanoma indicates
that high-penetrance variants in melanoma susceptibility genes
underlie predisposition to melanoma in some patients.
Identified high-penetrance variants for melanoma risk include
cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-
dependent kinase 4 (CDK4), an alternate reading frame (ARF)
of CDKN2A, and a locus on 1p22 [7,8]. However, these rare
variants appear to be responsible for only a small proportion of
melanoma susceptibility. Candidate gene association studies
and genome-wide association studies (GWASs) have identified
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several additional much more common but lower penetrance
gene variants that are associated with both pigmentation or
nevi and melanoma risk. Melanocortin 1 receptor (MC1R) is
associated with red hair, pale skin, freckling, and sun sensitivity
[9,10] and contributes to melanoma risk through both
pigmentary and nonpigmentary effects [9]. The oculocutaneous
albinism type II (OCA2) gene region on chromosome 15
demonstrates strong associations with eye and hair color
[11,12] and an association with melanoma risk[13,14].
Additional pigmentation-related genes associated with
melanoma risk are tyrosinase (TYR); tyrosinase-related protein
1 (TYRP1); solute carrier family 45, member 2 (SLC45A2); and
solute carrier family 24, member 4 (SLC24A4) [12,13,15]. A
region between MTAP and CDKN2A is associated with both
the number of cutaneous nevi and melanoma risk [6,16]. A
haplotype of the agouti signaling protein (ASIP) locus that is
associated with nevus count also significantly influences
melanoma risk[17–19]. Furthermore, some variants associated
with melanoma risk have no demonstrated association with
nevi or pigmentation phenotype[20]. These relatively common
individual genetic variants identified from previous candidate
gene association studies or GWASs generally have only weak
effects on melanoma risk (odds ratios [ORs] < 1.3)
[6,17,18,20,21]. We hypothesized that joint analysis of multiple
single-nucleotide polymorphisms (SNPs) could detect a larger
effect than those of the individual SNPs, and potentially
improve the predictive power of models based on conventional
phenotypic risk factors. To test our hypothesis, we sought to
validate the association of melanoma with 11 previously
identified SNPs in data sets from The University of Texas MD
Anderson Cancer Center melanoma case-control study
(MDACC), and the Harvard Medical School Nurse Health Study
(NHS) and Health Professionals Follow-Up Study (HPFS), and
to assess the predictive performance of these combined
variants, including relative to conventional phenotype risk
factors.
Methods
Design of the MD Anderson Cancer Center Study
The original discovery study was a hospital-based, case-
control investigation of cutaneous melanoma, for which non-
Hispanic white patients and controls were recruited at The
University of Texas MD Anderson Cancer Center between
March 1998 and August 2008. After genotyping samples from
3,156 participants, we determined that 1,804 melanoma
patients and 1,026 cancer-free controls (friends or
acquaintances of patients reporting to other clinics) had
adequate SNP data for analysis. The study protocols were
described previously [21]. All individuals gave informed consent
under The University of Texas MD Anderson Cancer
Center Institutional Review Board System (UTMDACC IRB
System) review board-approved protocol. Participants provided
their written informed consent to participate in this study.
Patients with all stages of cutaneous melanoma evaluated in
the Melanoma and Skin Cancer Center at MD Anderson were
eligible for inclusion. Data on sex, age, race, skin color, hair
color, eye color and tanning ability, and clinical prognostic
factors were collected from patient records. Pigmentation
information was collected from 931 patients and 1026 controls
via questionnaire.
Genotyping and Data Quality Control
The current study used high-density genotype data obtained
from 3,156 DNA samples of our melanoma patient and control
populations. The samples were genotyped by using the
Illumina HumanQmnil-Quad_v1-0_B array and details of
genotyping information and data quality control were described
in our previous study[21]. Finally, 818,237 genotyped SNPs
remained for the primary analysis. Imputation of ungenotyped
SNPs was performed using MACH[22] applied to genotype
data from all subjects. In total, we had 2,649,586 imputed or
directly genotyped SNPs eligible for an association study.
Among them, we extracted 11 SNPs that demonstrated
association with melanoma risk in previous studies for the
current analysis. These 11 SNPs were selected using the
method described in the Statistical Analysis section below. For
the 11 SNPs included in our final data analysis, four
(rs13016963, rs1335510, rs10830253, rs4911442) were
imputed and seven were directly genotyped. The most
significant SNP rs12913832 was directly genotyped.
Population from Harvard Cohort Studies
Both NHS and HPFS and their initial GWAS have been
described in previous studies [15,21]. Finally, we included 494
CM cases and 5628 controls.
Based on the genotyped SNPs and haplotype information in
the NCBI Build 35 of phase II Hapmap CEU data, we imputed
genotypes for 2.5 million SNPs using the program MACH. In
the validation study, we used the same 11 previously identified
melanoma risk SNPs as described in the discovery dataset to
observe their joint effect on melanoma risk.
Information on natural hair color at age 20 years was
collected in both the NHS and HPFS prospective
questionnaires, and information on natural eye color was
collected in the HPFS only. Tanning ability was collected in
NHS only. Hair color was divided into four categories (1=
blonde ; 2=red; 3= brown ; and 4=black), while eye color was
divided into three categories (1=blue/grey; 2=hazel/green;
3=brown/dark). Tanning ability was grouped into four
categories (1=practically none; 2=light tan; 3=average tan; and
4=deep tan).
Statistical Analysis
We used PubMed (http://www.ncbi.nlm.nih.gov/pubmed?
myncbishare=mdacclib&holding =mdacclib_fft) to search the
literature using the key words “melanoma and susceptibility
and GWAS” or “melanoma and genetic variants” to identify
candidate gene association studies or GWASs published prior
to December 2012; the studies found through this search
identified a total of 38 SNPs associated with melanoma risk.
These SNPs and their individual-SNP association results in the
MDACC data set are summarized in Table S1 in File S1. For
gene regions in which multiple SNPs were associated with
melanoma susceptibility, we selected the most significant SNP
(lowest P-value) within that gene region as representative to
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minimize the effect of linkage disequilibrium among the SNPs
we intended to combine to create a risk score. In total we
identified 15 independent candidate SNPs; 11 of these
candidate SNPs were available for analysis in all 3 data sets.
We counted the number of risk alleles for the selected SNPs
within each individual, weighted by risk coefficients (Table S2
in File S1), and we determined their joint effect on melanoma
susceptibility as described below.
We first performed logistic regression modeling to measure
the additive effect of each individual SNP on melanoma
susceptibility, without adjustment for any covariates. We then
combined multiple SNPs by summing the number of risk alleles
(0, 1, or 2) of each SNP, weighted by the effect sizes reported
in previous studies, to obtain a weighted polygenic risk score
(PRS). The analysis was first run in the discovery data set
(MDACC), with adjustments for sex, age, skin color (1-3=light,
4-6=medium, 7-10=dark), hair color (1 = blonde, 2 = red, 3 =
brown and 4 = black), eye color (1 = blue/gray, 2 = hazel/green
and 3 = brown/black) and tanning ability (ordinal trait 1 to 5),
and the analysis was then replicated in the NHS data set with
adjustments for age, tanning ability, skin color, and melanoma
family history; and in the HPFS data set with adjustments for
age, eye color, hair color, and melanoma family history. A
random effects model was used to pool the 3 data sets in a
meta-analysis with inverse variance weight. The Cochran Q
test and I2 index were used to evaluate heterogeneity across
the 3 studies[23]. Corrections for multiple testing were made
using Bonferroni adjustments.
To further assess the predictive value of PRS in the model,
we compared the discrimination of the following models: ①the
most significant SNP rs12913832, ② PRS, ③sex and age,
④sex, age, and pigmentation, and ⑤ sex, age, pigmentation,
and PRS. We evaluated the ability of the risk prediction models
to distinguish those who had disease from those who did not
using the area under the receiver operating characteristic curve
(AUC), for which higher values indicate better discrimination.
Increment in AUC in a model with conventional risk factors and
the PRS, compared with conventional risk factors alone, was
tested through the logistic regression procedure using SAS
software (SAS Institute, Cary, NC)[24]. Study participants were
divided into 3 categories (<20%, 20%-50%, and ≥ 50%) based
on predicted probabilities with or without PRS. We then
calculated the percentage of individuals who were reclassified
into higher- or lower-risk groups using model ⑤ rather than
model ④ to evaluate the usefulness of adding PRS to the
standard phenotypic model. To evaluate the significance of
novel biomarkers, we further calculated the integrated
discrimination improvement(IDI) and the net reclassification
improvement(NRI) as proposed by Pencina et al[25]. The IDI
estimates the new model’s improvement in average sensitivity
without sacrificing average specificity. The NRI estimates the
change of reclassification of subjects based on their predicted
probabilities of events using the new model with the option of
imposing meaningful risk categories.
All statistical analyses were performed using SAS Enterprise
Guide 4.3. All P values were 2 sided, and P values less than
0.05 were considered statistically significant.
Results
Baseline Characteristics of Melanoma Patients and
Controls
A total of 8,950 participants—2,829 from MDACC (one
individual with missing age information excluded), 3,693 from
NHS, and 2,428 from HPFS—were included in the current
analysis (Table 1). MDACC melanoma patients tended to have
lighter colored skin, eyes, and hair and lower tanning ability
than did the MDACC controls (Table 1, all P < 0.0001). Similar
results were observed in the NHS and HPFS data sets where
data were available. Data on family history of melanoma were
not collected in the MDACC population; melanoma patients
had a higher percentage of family history of melanoma than
controls in both the NHS and HPFS data sets (Table 1, all P <
0.0001).
Single SNP Association with Melanoma Risk
We replicated the associations of 11 SNPs with melanoma in
the MDACC data set at a nominal significance level of P< 0.05
without adjustment for any covariate. 9 SNPs remained
associated with melanoma after Bonferroni adjustment for
multiple testing of 11 SNPs (Table 2). Only 5 SNPs in the NHS
and 2 in the HPFS data sets were associated with melanoma
at a nominal significance level of P< 0.05. Only one SNP in
each validation data set reached significance after adjustment
for multiple testing. A meta-analysis of the pooled data sets
confirmed association of 5 SNPs with melanoma after
correction for multiple testing.
Association between PRS and Melanoma
The distribution of the total number of risk alleles across 11
SNPs was symmetric among the MDACC melanoma patients
and matched controls (range from 2 to 19 risk alleles); patients
carried more risk alleles than did controls (Figure S1 in File
S1). Participants in the MDACC data set carrying 15 or more
risk alleles were more than 5 times as likely to have melanoma
than were those carrying 6 or fewer risk alleles (OR = 5.12,
95% CI, 3.20-8.21; P < 0.0001; Table S3 in File S1). Per-unit
increase of PRS was associated with higher risk for melanoma
(OR = 1.17, 95% CI, 1.12-1.22; P = 2.17 × 10-13) after
adjustments for other covariates in the MDACC data set, and
the result was replicated in the NHS and HPFS data sets. In
the pooled data set, per-unit increase of PRS led to a 1.12-time
increase in melanoma risk (95% CI, 1.06-1.18; P = 4.63 × 10-5).
Participants in the highest tertile of PRS in the MDACC data
set were 2.13 times more likely to have melanoma than those
in the lowest tertile of PRS (95% CI, 1.69-2.68; P = 1.41 ×
10-10); this result was confirmed only in the NHS data set (OR =
1.55, 95% CI, 1.14-2.11; P = 5.00 × 10-3). A meta-analysis of
the three data sets confirmed an association of PRS with
melanoma susceptibility (OR = 1.69, 95% CI, 1.28-2.25; P =
2.24 × 10-4; Table 3). To observe whether participants with
extreme values of PRS had a high risk of having melanoma,
we divided the participants into 2 groups at a threshold of 95%
of PRS. After adjustments for sex, age, and pigmentation, we
found that those with a PRS above 95% had a 2.34-times
increased risk of having melanoma compared with those with a
Multiple SNPs Jointly Predict Melanoma Risk
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PRS below 95% (95% CI, 1.40-3.89; P=0.0011). In summary,
PRS as a continuous variable identified individuals with a
relatively high risk for melanoma susceptibility. No individual
SNP in Table 2 has an OR as high as 2.34. Therefore, joint
analysis of multiple variants identified individuals with a very
high risk for melanoma, which was not accomplished through
any single SNP test.
We additionally investigated whether the association
between PRS and melanoma was driven by the most
significant SNP in the MDACC data set (rs12913832 in
HERC2). After removing rs12913832 in a multivariate analysis
of the MDACC data set, the OR for the top tertile of PRS
decreased only slightly, from 2.13 to 2.11. Therefore, the
observed association between PRS and melanoma was not
uniquely accounted for by this individual SNP.
Because most common genetic variants for melanoma
susceptibility are also associated with phenotypic risk factors
such as pigmentation or nevi, we further observed the
relationship between PRS and each pigmentation factor. We
can find that PRS only accounted for 1-3.6% of variation of
pigmentation (all P-values<0.0001, Table S4 in File S1),
indicating that PRS was not fully correlated with skin color, eye
color or hair color but conferred effect on both pigmentation
factors and melanoma risk. Hence in the multivariate analysis,
we observed the effect of PRS on melanoma susceptibility with
adjustment for conventional phenotypic factors including
pigmentation factors and expected to determine if the genetic
Table 1. Demographic characteristics of the study participants*.
 MD Anderson Study, No. (%) (n = 2,829)&
Harvard Nurse Health Study, No. (%) (n =
3,693)
Harvard Health Professionals Follow-Up Study,
No. (%) (n = 2,428)
Characteristic
Melanoma
Patients(1,804) Controls(1,025) P Value
Melanoma
Patients(317) Controls(3,376) P Value
Melanoma
Patients(177) Controls(2,251) P Value
Sex          
Male 1,059 (58.7) 613 (59.8) 0.5989 0 (0) 0 (0) - 177 (100.0) 2,251 (100.0) -
Age, y (mean ±
SD) 52.1 ± 14.5 51.3 ± 12.6 0.1288 56.8 ± 6.8 57.2 ± 6.7 0.3241 61.2 ± 9.3 61.3 ± 8.5 0.7972
Skin color   < 0.0001   -   -
Light 553 (59.5) 457 (44.5)  - -  - -  
Medium 340 (36.6) 490 (47.8)  - -  - -  
Dark 37 (4.0) 79 (7.7)  - -  - -  
Eye color   < 0.0001   -   0.0947
Blue/gray 409 (44.0) 350 (34.1)  - -  63 (39.1) 746 (35.8)  
Brown 189 (20.3) 313 (30.5)  - -  39 (24.2) 676 (32.4)  
Hazel/green 332 (35.7) 363 (35.4)  - -  59 (36.7) 663 (31.8)  
Hair color   < 0.0001   < 0.0001   0.0169
Blonde 234 (25.9) 193 (18.9)  51 (16.8) 365 (11.4)  26 (16.2) 242 (11.6)  
Red 89 (9.8) 38 (3.7)  23 (7.6) 110 (3.4)  4 (2.5) 55 (2.6)  
Brown 541 (59.8) 732 (71.8)  225 (74.3) 2,655 (82.6)  121 (75.2) 1,589 (76.3)  
Black 41 (4.5) 57 (5.6)  4 (1.3) 83 (2.6)  10 (6.2) 196 (9.4)  
Tanning ability   < 0.0001      -
Practically none 62 (6.7) 120 (11.7)  35 (11.7) 235 (7.4)  - -  
Light tan 186 (20.2) 311 (30.3)  94 (31.4) 677 (21.3)  - -  
Average tan 340 (36.8) 322 (31.4)  119 (39.8) 1,470 (46.3)  - -  
Deep tan 335 (36.3) 273 (26.6)  51 (17.1) 796 (25.1)  - -  
Family history      < 0.0001   < 0.0001
First-degree
relative with
melanoma
-   63 (19.9) 265 (7.9)  22 (12.4) 111 (4.9)  
* Data in the table were not available for all patients and controls for pigmentation characteristics and family history in the MDACC and Harvard data sets.
& Pigmentation information was collected in 931 patients and 1026 controls via questionnaire.
doi: 10.1371/journal.pone.0085642.t001
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variants can contribute additionally to risk prediction beyond
conventional phenotypic factors.
The performance of our PRS model incorporating the
measured effect of 11 SNPs was compared with the most
Table 2. Association with melanoma risk for 11 previously identified melanoma risk variants.
SNP
Minor allele
frequency Gene
Risk
allele MD Anderson Study Harvard Nurse Health Study
Harvard Health Professionals
Follow-Up Study Pooled*
    OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
rs7412746 0.4452 ARNT T 1.18(1.06-1.31)
2.80 ×
10-3
1.24
(1.04-1.46)
1.40 ×
10-2 0.97 (0.78-1.21) 7.79 × 10
-1 1.15
(1.02-1.29) 1.88 × 10
-2
rs13016963 0.3834 ALS2CR12 A 1.13(1.01-1.26)
3.56 ×
10-2
1.04
(0.88-1.23)
6.57 ×
10-1 0.78 (0.62-0.98) 2.96 × 10
-2 0.99
(0.81-1.20) 9.13 × 10
-1
rs4636294 0.4781 LOC402359 A 1.23(1.10-1.37)
2.00 ×
10-4
1.00
(0.85-1.18)
9.84 ×
10-1 1.08 (0.87-1.33) 4.98 × 10
-1 1.11
(0.97-1.28) 1.18 × 10
-1
rs1335510 0.3919 LOC100418 T 1.26(1.12-1.40)
5.85 ×
10-5
1.03
(0.87-1.21)
7.66 ×
10-1 1.03 (0.83-1.28) 8.10 × 10
-1 1.12
(0.96-1.30) 1.51 × 10
-1
rs7023329 0.4696 MTAP A 1.26(1.13-1.41)
2.27 ×
10-5
1.01
(0.85-1.18)
9.55 ×
10-1 1.11 (0.90-1.38) 3.41 × 10
-1 1.13
(0.97-1.32) 1.03 × 10
-1
rs10830253 0.3398 TYR G 1.19(1.06-1.33)
3.40 ×
10-3
1.27
(1.07-1.50)
7.00 ×
10-3 1.54 (1.24-1.92) 1.00 × 10
-4 1.29
(1.12-1.48) 2.94 × 10
-4
rs1801516 0.1333 ATM G 1.23(1.05-1.44)
1.01 ×
10-2
1.16
(0.92-1.48)
2.16 ×
10-1 0.84 (0.62-1.14) 2.57 × 10
-1 1.10
(0.89-1.34) 3.75 × 10
-1
rs12913832 0.2250 HERC2 G 1.43(1.26-1.62)
5.60 ×
10-8
1.23
(1.01-1.49)
3.80 ×
10-2 1.12 (0.88-1.43) 3.44 × 10
-1 1.29
(1.12-1.48) 4.58 × 10
-4
rs258322 0.1203 CDK10 A 1.54(1.29-1.84)
1.41 ×
10-6
1.62
(1.28-2.05)
6.05 ×
10-5 1.28 (0.90-1.82) 1.70 × 10
-1 1.53
(1.34-1.74)
2.51 ×
10-10
rs4911442 0.1506 ASIP G 1.27(1.08-1.49)
3.30 ×
10-3
1.30
(1.03-1.65)
2.86 ×
10-2 1.32 (0.96-1.83) 8.58 × 10
-2 1.28
(1.14-1.45) 5.44 × 10
-5
rs132985 0.4518 PLA2G6 C 1.20(1.08-1.34)
1.20 ×
10-3
1.12
(0.95-1.32)
1.84 ×
10-1 1.20 (0.96-1.49) 1.04 × 10
-1 1.18
(1.08-1.28) 1.45 × 10
-4
SNP, single-nucleotide polymorphism
* A random effect model was used to pool the 3 data sets in meta-analysis.
doi: 10.1371/journal.pone.0085642.t002
Table 3. Association between weighted polygenic risk score (PRS) and melanoma risk in 3 data sets.
 Univariate analysis Multivariate analysis
Study No. OR for PRS (95% CI) P Value No. OR for PRS (95% CI) P Value
Continuous values       
MDACC* 2,830 1.19 (1.15-1.24) 3.71 × 10-23 1,949 1.17 (1.12-1.22) 2.17 × 10-13
NHS† 3,693 1.13 (1.08-1.19) 1.42 × 10-6 3,462 1.10 (1.04-1.16) 4.00 × 10-4
HPFS‡ 2,428 1.10 (1.03-1.18) 4.80 × 10-3 2,237 1.07 (1.00-1.15) 6.91 × 10-2
Pooled§ 8,951 1.15 (1.09-1.20) 5.39 × 10-8 7,468 1.12 (1.06-1.18) 4.63 × 10-5
Tertile 3 vs. Tertile 1       
MDACC* 2,830 2.34 (1.93-2.84) 5.46 × 10-18 1,949 2.13 (1.69-2.68) 1.41 × 10-10
NHS† 3,693 1.73 (1.30-2.30) 2.00 × 10-4 3,462 1.55 (1.14-2.11) 5.00 × 10-3
HPFS‡ 2,428 1.54 (1.06-2.24) 2.51 × 10-2 2,237 1.34 (0.90-2.00) 1.57 × 10-1
Pooled¶ 8,951 1.90 (1.46-2.48) 1.92 × 10-6 7,468 1.69 (1.28-2.25) 2.24 × 10-4
* Adjusted for age, sex, skin color (light, medium, dark), eye color (blue/gray, brown, hazel/green), hair color (blonde, red, brown, black), and tanning ability (always, usually,
moderate, minimal, rarely/never) in the multivariate analysis.
† Adjusted for age, hair color (blonde, red, brown, black), tanning ability (practically none, light tan, average tan, deep tan), and family history in the multivariate analysis.
‡ Adjusted for age, hair color (blonde, red, brown, black), eye color (blue/gray, brown, hazel/green), and family history in the multivariate analysis.
§P value for Cochrane Q statistic equals 0.0536, I2 heterogeneity index equals 65.83.
¶. P value for Cochrane Q statistic equals 0.0807, I2 heterogeneity index equals 60.28.
doi: 10.1371/journal.pone.0085642.t003
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significant SNP rs12913832 or other risk models using the
MDACC data set (Figure 1 and Table 4). The overall
discrimination of the PRS for melanoma was 0.62 (95% CI,
0.60-0.65), which was higher than that for the model with
rs12913832 (AUC=0.55, 95% CI, 0.53-0.57) and then that for
the model consisting of sex and age (AUC=0.51, 95% CI,
0.48-0.53), but approximately the same as that for the standard
phenotypic model consisting of sex, age, and pigmentation
(AUC=0.64, 95% CI, 0.61-0.66). Adding PRS to the
conventional risk model offered a small but significant
improvement to melanoma risk prediction (increase of AUC =
0.03, 95% CI, 0.02-0.05; P = 6.01 × 10-5). The overall
discrimination of the PRS plus conventional phenotypic factors
was 0.69 (95% CI, 0.64-0.69) in the MDACC data set. The
overall discrimination of the PRS for melanoma was higher in
the MDACC data set than that in the NHS and HPFS data sets,
probably due to the larger sample size of melanoma patients in
the former data set (Table S5 in File S1).
Results for reclassification of melanoma risk using the PRS
score in the MDACC data set are shown in Table 5. One
hundred thirteen control participants (11.0%) classified as
having a 50% or greater melanoma risk by the conventional
model were reclassified as having a 20% to 50% risk when
PRS was added to the model; 306 melanoma patients (17.0%)
classified as having a 20% to 50% risk were reclassified as
having a 50% or greater risk when PRS was incorporated. In
addition, 231 controls predicted to be at moderate risk
(20%-50%) for melanoma according to the model without
genotypic data were reclassified as high risk (>50%) in the
model including genotype. NRI was not significant (0.0109; P =
0.6076), but IDI, which estimates the new model’s
improvement in average sensitivity without sacrificing average
specificity, was significant (0.0350; P < 0.0001), indicating that
the addition of PRS on average might improve the predictive
ability of a clinical risk model using conventional risk factors.
Discussion
In a polygenic risk model, the joint effect of 11 independent
SNPs previously identified by GWAS significantly predicted
melanoma risk independent of traditional demographic and
pigmentation factors. The PRS improved the discrimination of
melanoma risk by a small margin compared to risk assessment
based on standard phenotypic risk factors. Our results suggest
that a risk model built with a modest set of biologic objectively
and directly measured risk factors, including a PRS, could
ultimately be incorporated into an improved model of
melanoma risk to supplement or even replace conventional
phenotypic risk factors, including assisting in risk stratification
to improve the efficacy and cost-effectiveness of large-scale
population-based screening programs. It is acknowledged,
however, that PRS in this study provided only a small
additional benefit in prediction and discrimination over
conventional phenotypic assessment; PRS was confirmed to
be in large part a surrogate measure of standard phenotypic
parameters for melanoma risk prediction because most
common variants in our study confer effects on pigmentation or
nevi as well as melanoma risk.
The National Cancer Institute developed a melanoma risk
prediction model by assessing demographics, pigmentation
and sun exposure factors among 718 white patients and 945
matched controls in Philadelphia and San Francisco[26]. Using
the constructed model, the AUC was 0.70 for women 50 years
or older and 0.80 for men 20 to 49 years old respectively.
European investigators constructed a model that included
common nevi, skin and hair color, freckles, and sunburns in
childhood, and in an external validation of the model’s
performance, the AUC was 0.79[27]. The prediction model we
built using MDACC phenotype data yielded an AUC of 0.64,
lower than previous studies. The reason for the lower AUC in
MDACC risk model might be that the current analysis didn’t
include the total number of nevi and presence of dysplastic
nevi, and/or because of differences in the population structure
of the cohorts investigated. The performance of the
conventional risk model included in the current study was
improved by including PRS, although the magnitude of
improvement was small. Our risk model using only PRS had
discriminability approximately equal to that of a conventional
phenotypic model. We acknowledge that the current relatively
high costs associated with genotyping and the relative low cost
and convenience associated with phenotypic assessment of
individual patients argues against routine incorporation of
genotyping into melanoma risk assessment of patients seen in
clinical practice. However, direct genotyping is increasingly
straightforward to perform at rapidly decreasing cost;
furthermore, accurate phenotypic assessment of large numbers
of patients in population-based screening programs may be
associated with significant costs of its own. In such a scenario,
especially if additional biologic measures of risk can also be
incorporated a model that includes limited genotyping to
provide a PRS with discrimination at least equal to that
obtained from interview data from questionnaires or from direct
physical examination could result in risk prediction at least as
accurate as a standard phenotypic model and at potentially
similar or even reduced cost.
We built our model to minimize effects of linkage
disequilibrium, and we assumed no or weak linkage
disequilibrium between different variants in the model. We ran
stepwise selection on our discovery data set and found that
only 9 SNPs still remained in the final logistic regression model
at significance level of P<0.05; the performance of risk
prediction based on those 9 SNPs was close to that based on
all 11 SNPs. To save genotyping cost, one could potentially
reduce the PRS to include only optimal SNPs instead of the
complete set for genetic testing. Our PRS risk model with 11
SNPs did not include any MC1R variants because they were
not available in the validation datasets. We included the
adjacent CDK10 SNP rs258322, which is in linkage
disequilibrium with the MC1R gene on chromosome 16. In the
MDACC data set, the most significant MC1R SNP (rs1805007)
accounted for the entire effect of the most significant CDK10
SNP (rs258322) (data not shown). Therefore, we predict that
an alternative model that included this MC1R SNP would
perform approximately as well as the model including the
CDK10 SNP. To test whether the joint effect of multiple
variants was dominated by the most significant SNP, we
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adjusted for the most significant SNP in the MDACC data set
(rs12913832) and found that the combined effect of the
remaining variants remained significant, with only a small
decrease in the OR; thus, the predictive ability of PRS is not
solely due to the effect of the most significant SNP.
Our study has limitations and therefore should be considered
preliminary, even with external validation. First, both the
discovery and validation groups were drawn from non-Hispanic
white populations in the United States; the model constructed
here in USA communities may not be applicable to other ethnic
Figure 1.  Receiver operating characteristic (ROC) curve for prediction of melanoma risk based on age and sex;
pigmentation, age, and sex; polygenic risk score (PRS); and PRS plus pigmentation, age, and sex(model).  
doi: 10.1371/journal.pone.0085642.g001
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groups in other countries. Second, the relatively small number
of cases from the Harvard Nurse Health study and the follow-
up study limits the power of our validation analyses. In addition,
the absence of males in the Harvard Nurse Health study and
the absence of females in the Follow-Up study could lead to
gender bias. For this reason, when we combined the three
datasets, we first adjusted for gender in the MDACC dataset
and then pooled the results using a random-effect model in
meta-analysis; this approach can minimize gender bias. Third,
our approach focused on common variants with weak effect but
did not incorporate much rarer variants with higher effect.
Fourth, our analysis did not take into account gene-gene and
gene-environmental interactions that widely exist in complex
diseases such as cancer[28]. Fourth, our risk prediction model
was only built in non-Hispanic whites. We assumed there was
no population substructure, and ethnicity was not adjusted for
in our analysis. Finally, there are ethical and legal issues
associated with genetic testing and risk prediction that would
need to be addressed before polygenic risk prediction could be
implemented on a population-wide basis[29].
In summary, these results while preliminary demonstrate that
joint analysis of multiple common, generally low-penetrance
SNPs can identify individuals with a very high risk for
melanoma susceptibility, and suggest that a polygenic profile
could ultimately be incorporated into an improved tool for
melanoma risk assessment that could supplement or
eventually even replace standard phenotypic variables,
including for population-based screening. Future investigations
should include polygenic profiling together with standardized
phenotypic assessment in prospective trials of melanoma
screening and prevention, and investigate the effects of the
addition of other genetic, epigenetic and biologic markers to
standard melanoma risk models.
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File S1.  Combined Supporting Information containing a
description of the previously published SNPs for
melanoma risk, their associations with melanoma
susceptibility in MDACC study, correlation between
polygenetic risk score (PRS) and pigmentation, and risk
prediction using PRS.
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Table 4. Risk prediction performance for different sets of predictors in the MD Anderson data set.
Model AUC (95% CI) Model Contrast ROC Contrast Estimation P Value
① rs12913832 0.55(0.53-0.57) - - -
②PRS 0.62 (0.60-0.65) ②-① 0.07(0.05-0.07) 1.53× 10-10
③Sex + age 0.51 (0.48-0.53) - - -
④Sex + age + pigmentation 0.64 (0.61-0.66) ④-③ 0.13 (0.10-0.16) 1.83 × 10-11
⑤Sex + age + pigmentation + PRS 0.69 (0.64-0.69) ⑤-④ 0.03 (0.02-0.05) 6.01 × 10-5
AUC, area under the receiver operating characteristic curve; PRS, polygenic risk score; ROC, receiver operating characteristic.
doi: 10.1371/journal.pone.0085642.t004
Table 5. Reclassification of participants’ predicted melanoma risk with and without weighted genetic variants in MD
Anderson Study *.
Predicted Risk† Predicted Risk Based on Known Risk Factors and PRS
Controls    
 <20% 20-50% ≥ 50%
<20% 0 0 0
20-50% 4 (0.4) 579 (56.4) 231 (22.5)
≥ 50% 0 113 (11.0) 99 (9.7)
Patients    
<20% 0 0 0
20-50% 0 372 (20.6) 306 (17.0)
≥ 50% 0 86 (4.8) 1,039 (57.6)
Net Reclassification Improvement of PRS for Melanoma Risk Up Down NRI P Value
Patients 306 86 0.1220 <0.0001
Controls 231 117 0.1111 <0.0001
Total - - 0.0109 0.6076
PRS, polygenic risk score; NRI, net reclassification improvement.
*. Integrated discriminant index equal to 0.0350 (P < 0.0001).
†. Predicted risk based on age, sex, eye color, skin color, hair color, and tanning ability.
doi: 10.1371/journal.pone.0085642.t005
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